用于预测转移性软组织肉瘤生存情况的新型代谢组学-生物体液生物标志物模型。

Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.

作者信息

Vignoli Alessia, Miolo Gianmaria, Tenori Leonardo, Buonadonna Angela, Lombardi Davide, Steffan Agostino, Scalone Simona, Luchinat Claudio, Corona Giuseppe

机构信息

Magnetic Resonance Center (CERM) and Department of Chemistry "Ugo Schiff", University of Florence, 50019 Sesto Fiorentino, Italy.

Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.

出版信息

iScience. 2023 Aug 19;26(10):107678. doi: 10.1016/j.isci.2023.107678. eCollection 2023 Oct 20.

DOI:10.1016/j.isci.2023.107678

PMID:37752948

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10518687/

Abstract

Soft tissue sarcomas (STSs) are rare malignant tumors that are difficult to prognosticate using currently available instruments. Omics sciences could provide more accurate and individualized survival predictions for patients with metastatic STS. In this pilot, hypothesis-generating study, we integrated clinicopathological variables with proton nuclear magnetic resonance (H NMR) plasma metabolomic and lipoproteomic profiles, capturing both tumor and host characteristics, to identify novel prognostic biomarkers of 2-year survival. Forty-five metastatic STS (mSTS) patients with prevalent leiomyosarcoma and liposarcoma histotypes receiving trabectedin treatment were enrolled. A score combining acetate, triglycerides low-density lipoprotein (LDL)-2, and red blood cell count was developed, and it predicts 2-year survival with optimal results in the present cohort (84.4% sensitivity, 84.6% specificity). This score is statistically significant and independent of other prognostic factors such as age, sex, tumor grading, tumor histotype, frailty status, and therapy administered. A nomogram based on these 3 biomarkers has been developed to inform the clinical use of the present findings.

摘要

软组织肉瘤（STSs）是罕见的恶性肿瘤，使用现有工具难以进行预后评估。组学科学可为转移性STSs患者提供更准确、个性化的生存预测。在这项探索性、假设生成性研究中，我们将临床病理变量与质子核磁共振（H NMR）血浆代谢组学和脂蛋白组学谱相结合，同时捕捉肿瘤和宿主特征，以识别2年生存的新型预后生物标志物。纳入了45例接受曲贝替定治疗、组织学类型以平滑肌肉瘤和脂肪肉瘤为主的转移性STSs（mSTS）患者。开发了一个综合乙酸盐、甘油三酯、低密度脂蛋白（LDL）-2和红细胞计数的评分系统，该系统在本队列中对2年生存的预测效果最佳（灵敏度84.4%，特异性84.6%）。该评分具有统计学意义，且独立于其他预后因素，如年龄、性别、肿瘤分级、肿瘤组织学类型、虚弱状态和所接受的治疗。基于这3种生物标志物开发了列线图，以指导本研究结果的临床应用。